FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 188 filers reported holding FATE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 4.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,099 | -75.2% | 2,405 | -44.4% | 0.00% | – |
| Q2 2023 | $20,596 | +61.2% | 4,327 | +93.1% | 0.00% | – |
| Q1 2023 | $12,773 | -3.1% | 2,241 | +71.6% | 0.00% | – |
| Q4 2022 | $13,178 | -95.7% | 1,306 | -90.5% | 0.00% | -100.0% |
| Q3 2022 | $307,000 | +3311.1% | 13,730 | +3631.0% | 0.00% | – |
| Q2 2022 | $9,000 | -18.2% | 368 | +22.7% | 0.00% | – |
| Q1 2022 | $11,000 | -60.7% | 300 | -37.5% | 0.00% | – |
| Q4 2021 | $28,000 | -31.7% | 480 | -30.7% | 0.00% | – |
| Q3 2021 | $41,000 | -39.7% | 693 | -12.3% | 0.00% | – |
| Q2 2021 | $68,000 | +58.1% | 790 | +51.3% | 0.00% | – |
| Q1 2021 | $43,000 | +290.9% | 522 | +353.9% | 0.00% | – |
| Q4 2020 | $11,000 | +1000.0% | 115 | +576.5% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 17 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | -93.3% | 17 | -98.2% | 0.00% | – |
| Q3 2018 | $15,000 | +50.0% | 922 | +7.2% | 0.00% | – |
| Q2 2018 | $10,000 | – | 860 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |